https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg00LRuashttps://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svgLRuas2022-11-30 08:47:052022-11-30 08:47:05ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg00LRuashttps://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svgLRuas2022-11-30 08:46:422022-11-30 09:24:39NXI Therapeutics Press Release NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg00Marketing Teamhttps://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svgMarketing Team2022-11-29 09:27:572022-11-29 09:27:57Biocomposites adds Mexico to its list of countries where STIMULAN is approved as an antibiotic carrier for use in bone and soft tissue
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg00Marketing Teamhttps://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svgMarketing Team2022-11-22 10:29:482022-11-22 10:29:48ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg00LRuashttps://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svgLRuas2022-11-17 09:07:492022-11-23 15:28:34Dan Mahony & Gareth Powell – Global healthcare investing: Can hindsight hone the crystal ball for the future? A fireside chat moderated by Amy Brown, Evaluate Vantage
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg00LRuashttps://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svgLRuas2022-11-16 10:02:472022-11-16 10:02:47Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg00LRuashttps://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svgLRuas2022-11-15 10:43:162022-11-15 10:43:16Destiny Pharma plc – XF-73 Dermal infection project advances into clinically enabling safety study as part of ongoing agreement with US Government’s NIAID
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg00LRuashttps://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svgLRuas2022-11-15 09:00:002022-11-15 09:00:00Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Google Analytics Cookies
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
Other external services
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them: